Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea

Current Medical Research and Opinion

Volumn 32, Issue 5, 2016, Pages 807-816

  Lozano Ortega, G ^a   Goring, S ^a   Bennett, H A ^a   Bergenheim, K ^b   Sternhufvud, C ^b   Mukherjee, J ^c  

^a ICON PLC   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Network meta analysis; SGLT2 inhibitors; Triple therapy; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIPHASIC INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; MEGLITINIDE; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SULFONYLUREA DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WEIGHT REDUCTION; ANALYSIS; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; META ANALYSIS; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84964778207     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1135110     Document Type: Article

References (55)

1. Hamman RF. Genetic and environmental determinants of non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992;8:287-338
2. World Health Organization. Diabetes. World Health Organization, September 2012. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/[Last accessed 30 June 2014]
3. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011;378:169-81
4. Mathers C, Boerma T, Fat DM, et al. The Global Burden of Disease, 2008. World Health Organization. http://www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full.pdf
5. National Institute for Health and Clinical Excellence. Type 2 diabetes: The management of type 2 diabetes. Report No.: NICE clinical guideline 87-type 2 diabetes. London, UK: National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE, May 2009
6. Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis. CMAJ 2009;180:385-97
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
8. European Medicines Agency. Forxiga: EPAR-Information. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002322/WC500136026.pdf [Last accessed 16 September 2013]
9. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31
10. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
11. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124-36
12. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
13. Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea. Identifier NCT01128153. Bethesda (MA): 2013. ClinicalTrials.gov [Last accessed 30 June 2014]
14. CADTH Optimal Use Report-Third-line pharmacotherapy for Type 2 Diabetes-Update. CADTH 2013 Vol.3, no.1b. Available at: http://www.cadth.ca/media/pdf/OP0512-Diabetes%20Update-Third-line-e.pdf [Last accessed 30 June 2014]
15. Canadian Agency for Drugs and Technologies in Health. Clinical Review: Third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea. CADTH, 2010. Available at: https://www.cadth.ca/second-and-third-line-therapiestype-2-diabetes [Last accessed 6 January 2014]
16. Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. NICE, 2011. Available at: www.nicedsu.org.uk [Last accessed 30 June 2014]
17. Alshaikh AR. Comparison of basal insulin added to oral agents versus twice daily premixed insulin as initial insulin therapy for type 2 diabetes. Pak J Med Sci 2006;22:14-17
18. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, randomized trial. Am J Med 2004;116:230-5
19. Bell DS, Dharmalingam M, Kumar S, Sawakhande RB. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). Diabetes Obes Metab 2011;13:800-5
20. Bergenstal R, Lewin A, Bailey T, et al. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009;25:65-75
21. Davies MJ, Thaware PK, Tringham JR, et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. Diabet Med 2007;24:714-19
22. Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
23. Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol 2009;8:15
24. Goudswaard AN, Stolk RP, Zuithoff P, et al. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract 2004;53:393-9
25. Hartemann-Heurtier A, Halbron M, Golmard JL, et al. Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes Res Clin Pract 2009;86:37-43
26. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005;143:559-69
27. Herman WH, Buse JB, Arakaki RF, et al. Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. Endocr Pract 2011;17:563-7
28. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
29. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9
30. Liu SC, Chien KL, Wang CH, et al. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. Endocr Pract 2013;19:980-8
31. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 2007;50:259-67
32. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care 2013;36:2508-15
33. Stehouwer MH, DeVries JH, Lumeij JA, et al. Combined bedtime insulin-daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate-A randomised trial. Diabetes Metab Res Rev 2003;19:148-52
34. Strojek K, Bebakar WMW, Khutsoane DT, et al. Oncedaily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009;25:2887-94
35. Charpentier G, Halimi S. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab 2009;11:844-54
36. AstraZeneca BMS. A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin and Sulfonylurea in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Combination of Metformin and Sulfonylurea. ClinicalTrials.gov, 8 July 2012. Available at: http://clinicaltrials.gov/ct2/show/results/NCT01128153? sect=X6015#outcome1 [Last accessed 30 June 2014]
37. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45
38. Home P, Stewart M, Yang F, et al. 52-Week Efficacy of Albiglutide vs Placebo and vs Pioglitazone in Triple Therapy (Background Metformin and Glimepiride) in People with Type 2 Diabetes: HARMONY5 Study (58-LB). American Diabetes Association 73rd Scientific Sessions, 2013
39. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
40. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
41. Lukashevich V, Prato SD, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab 2014;16:403-9
42. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study. Diabet Med 2011;28:1352-61
43. Round E, Shentu Y, Golm GT. Safety and Efficacy of Sitagliptin Added to the Combination of Sulfonylurea and Metformin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (1148-P). American Diabetes Association 73rd Scientific Sessions, 2013
44. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009;52:2046-55
45. Matthaei S, Rohwedder K, Grohl A, Johnsson E. Dapagliflozin improves glycaemic control and reduces body weight as add-on therapy to metformin plus sulphonylurea (PS-073). Diabetologia 2013:56
46. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract 2013;67:1267-82
47. Lu CH, Wu TJ, Shih KC, et al. Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus. J Formos Med Assoc 2013;112:144-50
48. Food and Drug Administration. Guidance to Industry Developing Products for Weight Management. 2007. Published by the FDA. Available at: http://www.fda.gov/downloads/Drugs/⋯/Guidances/ucm071612.pdf Last accessed 30 June 2014
49. A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication. ClinicalTrials.gov, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT 01195662 [Last accessed 30 September 2013]
50. A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB). ClinicalTrials.gov, 2013. Available at: http://clinicaltrials. gov/ct2/show/NCT01137474 [Last accessed 30 September 2013]
51. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012;157: 601-10
52. Li Y, Hu Y, Ley SH, et al. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care 2014;37:3106-13
53. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patientcentered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
54. Lambert PC, Sutton AJ, Burton PR, et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005;24:2401-28
55. Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab 2013;15:213-23